News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Videos|January 5, 2023

Impact of Routes of Administration on Contraceptive Adherence

Author(s)Jenna Beckham, MD, MSPH, FACOG, Thomas Kimble, MD

Jenna Beckham, MD, MSPH, FACOG, and Thomas Kimble, MD, discuss patient misconceptions around contraceptive options and the impact on adherence.

Episodes in this series

EP. 1 Prevalence of Contraceptive Use in the US

EP. 1 Prevalence of Contraceptive Use in the US

EP. 2 Initiating Contraception Conversations With Patients

EP. 2 Initiating Contraception Conversations With Patients

EP. 3 Communicating With Patients About Contraceptives

EP. 3 Communicating With Patients About Contraceptives

EP. 4 Role of Pharmacists and Other Healthcare Professionals in Contraceptive Counseling

EP. 4 Role of Pharmacists and Other Healthcare Professionals in Contraceptive Counseling

EP. 5 Use of Hormonal Contraceptive Agents

EP. 5 Use of Hormonal Contraceptive Agents

EP. 6 Contraception for Patients With Higher BMI

EP. 6 Contraception for Patients With Higher BMI

EP. 7 Cardiovascular Risks Associated With Contraceptive Use

EP. 7 Cardiovascular Risks Associated With Contraceptive Use

EP. 8 Overview of Approved Contraceptives: Drospirenone

EP. 8 Overview of Approved Contraceptives: Drospirenone

EP. 9 Additional Methods of Contraception

EP. 9 Additional Methods of Contraception

EP. 10 Hormonal Patch and Vaginal Gel Contraceptives

EP. 10 Hormonal Patch and Vaginal Gel Contraceptives

EP. 11 Impact of Routes of Administration on Contraceptive Adherence

EP. 11 Impact of Routes of Administration on Contraceptive Adherence

EP. 12 Benefits of Recently Approved Contraceptives

EP. 12 Benefits of Recently Approved Contraceptives

EP. 13 Educational Resources on Contraceptive Options

EP. 13 Educational Resources on Contraceptive Options

EP. 14 Unmet Needs in Contraception

EP. 14 Unmet Needs in Contraception

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

FDA: Levonorgestrel/ethinyl estradiol birth control patch sees update to labeled strength

FDA: Levonorgestrel/ethinyl estradiol birth control patch sees update to labeled strength

ByJoshua Fitch, Senior Editor

June 19th 2026

The top headlines in women's health from May 2026

The top headlines in women's health from May 2026

ByJoshua Fitch, Senior Editor

May 29th 2026

Mifepristone via telehealth, mail order can continue amid lawsuit, Supreme Court says | | Image credit: © SolsticeStudio - stock.adobe.com

Mifepristone via telehealth, mail order can continue amid lawsuit, Supreme Court says

ByJoshua Fitch, Senior Editor

May 15th 2026

Ovaprene phase 3 interim data supports potential of monthly hormone-free contraceptive | Image credit: Stock.Adobe.com

Ovaprene phase 3 interim data supports potential of monthly hormone-free contraceptive

ByJoshua Fitch, Senior Editor

Published: May 13th 2026 | Updated: June 17th 2026

Contraceptive vaginal system for use up to 1 year launches in Canada | Image Credit: © LIGHTFIELD STUDIOS - © LIGHTFIELD STUDIOS - stock.adobe.com.

Contraceptive vaginal system for use up to 1 year launches in Canada

ByJoshua Fitch, Senior Editor

April 7th 2026

Latest CME

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Trending on Contemporary OB/GYN

Multi-modality impact of elinzanetant's effect on postmenopausal sleep disturbance

NIRVANA: Elinzanetant cuts objective wakefulness in menopausal women

FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections

FDA: Levonorgestrel/ethinyl estradiol birth control patch sees update to labeled strength

Q+A: Fiona Baker, PhD, on sleep disturbances in menopause and the role of vasomotor symptoms